PARI Pharma GmbH


    • Company type:
      • Research & Development
    • Year founded:
    • not available
    • Employees (at the site):
    • not available
    • Turnover range:
    • not available
    • Products/services:
    • Aerosol delivery systems;
      Development and commercialization of optimizes drug and device combinations

    • Core competencies:
    • PARI Pharma is developing a portfolio of inhalable drugs to treat respiratory diseases such as cystic fibrosis, bronchiolitis obliterans, asthma, and COPD as well as rhinosinusitis. The company is focusing on improving the therapeutic efficiency of existing treatments by combining PARI Pharma?s proprietary eFlow Technology Nebulizer Systems with in-house formulation development and optimization know-how. Goal is to maximize treatment efficiency and simultaneously minimize the treatment time to ultimately improve patient compliance. Besides the company?s proprietary drug development programs, PARI Pharma partners with selected pharma and biotech companies to develop new and improved therapies based on the partner?s proprietary compounds and PARI Pharma?s eFlow Technology Nebulizer Systems.

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Biotechnology
      • Medical Technology: Medical Technology
    • Certification:
    • TÜV, CE, 510(k), DIN EN ISO 13485-2007, Medizinprodukterichtlinie 93/42/EWG, Certificate of GMP compliance for a manufacturer

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Martin Knoch (Mr.)
      - Management